Magellan Health (NASDAQ:MGLN) will be releasing its earnings data before the market opens on Thursday, February 22nd. Analysts expect Magellan Health to post earnings of $2.30 per share for the quarter.
Magellan Health (NASDAQ:MGLN) opened at $97.60 on Tuesday. Magellan Health has a 52 week low of $64.05 and a 52 week high of $102.70. The company has a quick ratio of 2.21, a current ratio of 2.28 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $2,346.53, a price-to-earnings ratio of 25.75, a PEG ratio of 1.14 and a beta of 0.52.
In related news, CEO Mostafa Kamal sold 2,180 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $92.00, for a total transaction of $200,560.00. Following the sale, the chief executive officer now owns 2,180 shares of the company’s stock, valued at approximately $200,560. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Clapper Caskie Lewis sold 59,313 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $93.99, for a total value of $5,574,828.87. Following the sale, the insider now directly owns 48,474 shares in the company, valued at approximately $4,556,071.26. The disclosure for this sale can be found here. In the last three months, insiders have sold 113,953 shares of company stock worth $10,797,505. 5.00% of the stock is currently owned by company insiders.
Several brokerages have recently issued reports on MGLN. ValuEngine upgraded Magellan Health from a “hold” rating to a “buy” rating in a research note on Sunday, December 31st. BidaskClub lowered Magellan Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, December 19th. Raymond James Financial reiterated a “hold” rating on shares of Magellan Health in a research note on Saturday, December 2nd. KeyCorp set a $105.00 price target on Magellan Health and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, Zacks Investment Research upgraded Magellan Health from a “hold” rating to a “strong-buy” rating and set a $112.00 price target on the stock in a research note on Wednesday, December 13th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $96.00.
COPYRIGHT VIOLATION NOTICE: “Magellan Health (MGLN) Scheduled to Post Quarterly Earnings on Thursday” was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2018/02/20/magellan-health-mgln-scheduled-to-post-quarterly-earnings-on-thursday.html.
Magellan Health Company Profile
Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).
Receive News & Ratings for Magellan Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health and related companies with MarketBeat.com's FREE daily email newsletter.